CTI Appoints Clinical Trial Ops VP

Melanie A. Bruno, Ph.D., has been appointed vice president of Clinical Trial Operations at CTI Clinical Trial and Consulting Services. Dr. Bruno has more than 18 years of clinical and regulatory drug development experience in the biopharma and clinical research industries.

Dr. Bruno joins the company from Kendle, where she served as vice president of Global Regulatory and Medical Affairs, vice president of Global Regulatory, Site and Medical Affairs and vice president of Global Regulatory and Quality for the past 9 years. In these roles, she provided oversight and management of staff in more than 38 countries, executing full service (Phase I-IV) and function service models in safety/pharmacovigilance and medical writing. Prior to Kendle, Dr. Bruno spent two years at Eli Lilly in U.S. Regulatory Affairs and six years at Procter & Gamble Pharmaceuticals in Regulatory Affairs.

“Dr. Bruno will be serving in a new position at CTI driven by the growth, complexity and globalization in our work that we have experienced over the past few years,” says Kevin Schwarz, senior vice president Clinical Trial Operations of CTI. “Dr. Bruno’s broad experience and proven success in the leadership and development of multiple clinical and regulatory research functions will be a great asset to CTI.”